167 related articles for article (PubMed ID: 35232230)
1. Effectiveness of crizotinib versus entrectinib in
Tremblay G; Groff M; Iadeluca L; Daniele P; Wilner K; Wiltshire R; Bartolome L; Usari T; Cappelleri JC; Camidge DR
Future Oncol; 2022 Jun; 18(17):2063-2074. PubMed ID: 35232230
[No Abstract] [Full Text] [Related]
2. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs MG; Shaw AT; de Braud F; Rolfo C; Ahn MJ; Wolf J; Seto T; Cho BC; Patel MR; Chiu CH; John T; Goto K; Karapetis CS; Arkenau HT; Kim SW; Ohe Y; Li YC; Chae YK; Chung CH; Otterson GA; Murakami H; Lin CC; Tan DSW; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Doebele RC;
Lancet Oncol; 2020 Feb; 21(2):261-270. PubMed ID: 31838015
[TBL] [Abstract][Full Text] [Related]
3. Matching-adjusted indirect comparison: entrectinib versus crizotinib in
Chu P; Antoniou M; Bhutani MK; Aziez A; Daigl M
J Comp Eff Res; 2020 Aug; 9(12):861-876. PubMed ID: 32648475
[No Abstract] [Full Text] [Related]
4. Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in
Doebele RC; Perez L; Trinh H; Martinec M; Martina R; Riehl T; Krebs MG; Meropol NJ; Wong WB; Crane G
J Comp Eff Res; 2021 Dec; 10(17):1271-1282. PubMed ID: 34427452
[No Abstract] [Full Text] [Related]
5. Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidence.
Nadal E; Rifi N; Kane S; Mbacke S; Starkman L; Suero B; Le H; Samjoo IA
Lung Cancer; 2024 Jun; 192():107816. PubMed ID: 38749072
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
Michels S; Massutí B; Schildhaus HU; Franklin J; Sebastian M; Felip E; Grohé C; Rodriguez-Abreu D; Abdulla DSY; Bischoff H; Brandts C; Carcereny E; Corral J; Dingemans AC; Pereira E; Fassunke J; Fischer RN; Gardizi M; Heukamp L; Insa A; Kron A; Menon R; Persigehl T; Reck M; Riedel R; Rothschild SI; Scheel AH; Scheffler M; Schmalz P; Smit EF; Limburg M; Provencio M; Karachaliou N; Merkelbach-Bruse S; Hellmich M; Nogova L; Büttner R; Rosell R; Wolf J
J Thorac Oncol; 2019 Jul; 14(7):1266-1276. PubMed ID: 30978502
[TBL] [Abstract][Full Text] [Related]
7. A case of lung adenocarcinoma with a novel CD74-ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib.
Hashiguchi MH; Sato T; Watanabe R; Kagyo J; Matsuzaki T; Domoto H; Kato T; Nakahara Y; Yokose T; Hiroshima Y; Shiomi T
Thorac Cancer; 2021 Sep; 12(18):2504-2507. PubMed ID: 34319660
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of crizotinib in patients with
Nogami N; Nakamura A; Shiraiwa N; Kikkawa H; Emir B; Wiltshire R; Morise M
Future Oncol; 2023 Dec; 19(37):2453-2463. PubMed ID: 37605861
[TBL] [Abstract][Full Text] [Related]
9. Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology-Based Observational Study.
Waterhouse D; Iadeluca L; Sura S; Wilner K; Emir B; Krulewicz S; Espirito J; Bartolome L
Target Oncol; 2022 Jan; 17(1):25-33. PubMed ID: 34964940
[TBL] [Abstract][Full Text] [Related]
10. First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer.
Shen L; Qiang T; Li Z; Ding D; Yu Y; Lu S
Cancer Med; 2020 May; 9(10):3310-3318. PubMed ID: 32167664
[TBL] [Abstract][Full Text] [Related]
11. Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study.
Zhang Y; Zhang X; Zhang R; Xu Q; Yang H; Lizaso A; Xu C; Liu J; Wang W; Ou SI; Zhang J; Song Z; Yang N
BMC Med; 2021 Sep; 19(1):206. PubMed ID: 34511132
[TBL] [Abstract][Full Text] [Related]
12. Lung Injury Induced by Crizotinib and Entrectinib in a Patient with ROS1-rearranged Non-small-cell Lung Cancer.
Nishiyama Y; Omori S; Matsumoto H; Komiya K; Hiramatsu K
Intern Med; 2023 Dec; 62(23):3507-3510. PubMed ID: 37062732
[TBL] [Abstract][Full Text] [Related]
13. Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.
Wu YL; Yang JC; Kim DW; Lu S; Zhou J; Seto T; Yang JJ; Yamamoto N; Ahn MJ; Takahashi T; Yamanaka T; Kemner A; Roychowdhury D; Paolini J; Usari T; Wilner KD; Goto K
J Clin Oncol; 2018 May; 36(14):1405-1411. PubMed ID: 29596029
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9-edited ROS1 + non-small cell lung cancer cell lines highlight differential drug sensitivity in 2D vs 3D cultures while reflecting established resistance profiles.
Terrones M; Deben C; Rodrigues-Fortes F; Schepers A; de Beeck KO; Van Camp G; Vandeweyer G
J Transl Med; 2024 Mar; 22(1):234. PubMed ID: 38433235
[TBL] [Abstract][Full Text] [Related]
15. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic
Dziadziuszko R; Krebs MG; De Braud F; Siena S; Drilon A; Doebele RC; Patel MR; Cho BC; Liu SV; Ahn MJ; Chiu CH; Farago AF; Lin CC; Karapetis CS; Li YC; Day BM; Chen D; Wilson TR; Barlesi F
J Clin Oncol; 2021 Apr; 39(11):1253-1263. PubMed ID: 33646820
[TBL] [Abstract][Full Text] [Related]
16. TRUST-II: a global phase II study of taletrectinib in
Nagasaka M; Ohe Y; Zhou C; Choi CM; Yang N; Liu G; Felip E; Pérol M; Besse B; Nieva J; Raez L; Pennell NA; Dimou A; Marinis F; Ciardiello F; Seto T; Hu Z; Pan M; Wang W; Li S; Ou SI
Future Oncol; 2023 Jan; 19(2):123-135. PubMed ID: 36877099
[TBL] [Abstract][Full Text] [Related]
17. Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib.
De Giglio A; Lamberti G; Facchinetti F; Genova C; Andrini E; Dal Bello MG; Tiseo M; Metro G; Chiari R; Ricciuti B
Clin Lung Cancer; 2020 Sep; 21(5):e478-e487. PubMed ID: 32409267
[TBL] [Abstract][Full Text] [Related]
18. Serial Cell-Free DNA Sequencing in
Choudhury NJ; Jun Woo H; Chen M; Shah R; Donoghue M; Berger M; Drilon A
JCO Precis Oncol; 2024 Jun; 8():e2300721. PubMed ID: 38848521
[TBL] [Abstract][Full Text] [Related]
19. Crizotinib in
Landi L; Chiari R; Tiseo M; D'Incà F; Dazzi C; Chella A; Delmonte A; Bonanno L; Giannarelli D; Cortinovis DL; de Marinis F; Borra G; Morabito A; Gridelli C; Galetta D; Barbieri F; Grossi F; Capelletto E; Minuti G; Mazzoni F; Verusio C; Bria E; Alì G; Bruno R; Proietti A; Fontanini G; Crinò L; Cappuzzo F
Clin Cancer Res; 2019 Dec; 25(24):7312-7319. PubMed ID: 31416808
[TBL] [Abstract][Full Text] [Related]
20. Therapeutical Options in ROS1-Rearranged Advanced Non Small Cell Lung Cancer.
Stanzione B; Del Conte A; Bertoli E; De Carlo E; Revelant A; Spina M; Bearz A
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]